Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia

References

• StevensDLBisnoALChambersHFIDSA guidelines: practice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541101373140616231249
   PubMed Web of Science ®Google Scholar
• DrydenMSComplicated skin and soft tissue infectionsJ Antimicrob Chemother201065Suppl 3iii35iii4420876627
   PubMed Web of Science ®Google Scholar
• EronLJLipskyBALowDEManaging skin and soft tissue infections:expert panel recommendations on key decision pointsJ Antimicrob Chemother200352Suppl 1i3i1714662806
   PubMedGoogle Scholar
• DiekemaDJPfallerMASchmitzFJSurvey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program,1997–1999Clin Infect Dis200132S114S13211320452
   PubMed Web of Science ®Google Scholar
• Di NubileMJLipskyBAComplicated infections of the skin and skin structures: when the infection is more than skin deepJ Antimicrob Chemother200453Suppl 2ii37ii5015150182
   PubMedGoogle Scholar
• JevonsMPCelbenin-resistant staphylococciBr Med J19611124125
   Web of Science ®Google Scholar
• WenzelRPNettlemanMDJonesRNMethicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measuresAm J Med199191221S227S1928168
   PubMed Web of Science ®Google Scholar
• GrundmannHAires-de-SousaMBoyceJEmergence and resurgence of methicillin-resistant Staphylococcus aureus as a public health threatLancet200636887488516950365
   PubMed Web of Science ®Google Scholar
• MoetGJJonesRNBiedenbachDJContemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004)Diagn Microbiol Infect Dis20075771317059876
   PubMed Web of Science ®Google Scholar
• BruceAMSpencerJMPrevalence of community-acquired methicillin-resistant Staphylococcus aureus in a private dermatology officeJ Drugs Dermatol2008775175518720691
   PubMed Web of Science ®Google Scholar
• DrydenMSComplicated skin and soft tissue infections caused by MRSA: epidemiology, risk factors and presentationSurg Infect20089Suppl 1S3S10
   PubMed Web of Science ®Google Scholar
• ChenCJHuangYCNew epidemiology of Staphylococcus aureus infection in AsiaClin Microbiol Infect201420760562324888414
   PubMed Web of Science ®Google Scholar
• YoungDMHarrisHWCharleboisEDAn epidemic of MRSA soft tissue infections among medically underserved patientsArch Surg200413994795115381611
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med200635566667416914702
   PubMed Web of Science ®Google Scholar
• RayGTSuayaJABaxterRIncidence, microbiology and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based studyBMC Infect Dis20131325223721377
   PubMed Web of Science ®Google Scholar
• Antimicrobial Resistance Surveillance in Europe 2012 Available from: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdfAccessed January 9, 2015
   Google Scholar
• DrydenMAndrasevicATBassettiMA European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practiceClin Microbiol Infect201016Suppl 133020222890
   PubMed Web of Science ®Google Scholar
• SaderHSFarrellDJJonesRNAntimicrobial susceptibility of gram-positive cocci isolated from skin and skin-structure infections in European medical centresInt J Antimicrob Agents201036283220444576
   PubMed Web of Science ®Google Scholar
• JohnsonAPMethicillin-resistant Staphylococcus aureus: the European landscapeJ Antimicrob Chemother201166Suppl 4iv43iv4821521706
   PubMed Web of Science ®Google Scholar
• Health Protection AgencySurveillance of Healthcare Associated Infections Report 2008 Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1216193833496Accessed April 29, 2014
   Google Scholar
• Health Protection AgencyHealthcare-associated infections and antimicrobial resistance: 2009/10 Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1281954479045Accessed April 29, 2014
   Google Scholar
• LiJSSextonDJMickNProposed modifications to the Duke criteria for the diagnosis of infective endocarditisClin Infect Dis20003063363810770721
   PubMed Web of Science ®Google Scholar
• WhiteBSeatonRAComplicated skin and soft tissue infections: literature review of evidence for and experience with daptomycinInfect Drug Resist2011411512721753891
   PubMedGoogle Scholar
• EisensteinBITreatment challenges in the management of complicated skin and soft-tissue infectionsClin Microbiol Infect200814Suppl 2172518226086
   PubMedGoogle Scholar
• GemmelCGEdwardsDIFraiseAPGuidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UKJ Antimicrob Chemother200657458960816507559
   PubMed Web of Science ®Google Scholar
• HernandezPOLemaSTyringSKMendozaNCeftaroline in complicated skin and skin-structure infectionsInfect Drug Resist20125233522294860
   PubMedGoogle Scholar
• BoucherHMillerLGRazonableRRSerious infections caused by methicillin-resistant Staphylococcus aureusClin Infect Dis201051Suppl 2S183S19720731576
   PubMed Web of Science ®Google Scholar
• MandellGLBennettJEDolinRMandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases7th edPhiladelphia, PAChurchill Livingstone, Elsevier2009
   Google Scholar
• TorokEMoranECookeFOxford Handbook of Infectious Diseases and MicrobiologyOxford, UKOxford University Press2009
   Google Scholar
• ManuelRJTuckALowesAPalletASouthampton Public Health Laboratory. Detection of teicoplanin resistance in UK EMRSA-17 strainsJ Antimicrob Chemother20025061089109012461040
   PubMedGoogle Scholar
• WatkinsRRLemonovichTLDiagnosis and management of community-acquired pneumonia in adultsAm Fam Physician201183111299130621661712
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionFastStats pneumonia: deaths and mortality Available from: http://www.cdc.gov/nchs/fastats/pneumonia.htmAccessed April 29, 2014
   Google Scholar
• LimWSBaudouinSVGeorgeRCPneumonia guidelines committee of the BTS standards of care committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009Thorax200964Suppl 315519103870
   PubMed Web of Science ®Google Scholar
• FileTMJrMarrieTJBurden of community-acquired pneumonia in North American adultsPostgrad Med2010122213014120203464
   PubMed Web of Science ®Google Scholar
• MillettERCQuintJKSmeethLDanielRMThomasSLIncidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based studyPLoS One201389e7513124040394
   PubMed Web of Science ®Google Scholar
• JokinenCHeiskanenLJuvonenHIncidence of community-acquired pneumonia in the population of four municipalities in eastern FinlandAm J Epidemiol19931379771888317455
   PubMed Web of Science ®Google Scholar
• FroesFCommunity-acquired pneumonia in adults in mainland Portugal – incidence and mortality in hospital inpatients between 1998 and 2000Rev Port Pneumol2003187194 Portugese14685629
   PubMedGoogle Scholar
• TrotterCLStuartJMGeorgeRIncreasing hospital admissions for pneumonia, EnglandEmerg Infect Dis200814727e3318439353
   PubMed Web of Science ®Google Scholar
• NiedermanMSChallenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacinClin Infect Dis200541Suppl 2S158S16615942882
   PubMedGoogle Scholar
• NiedermanMSMandellLAAnzuetoAGuidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and preventionAm J Respir Crit Care Med20011631730175411401897
   PubMed Web of Science ®Google Scholar
• MongkolrattanothaiKBoyleSKahanaMDDaumRSSevere Staphylococcus aureus infections caused by clonally related community acquired methicillin-susceptible and methicillin-resistant isolatesClin Infect Dis2003371050105814523769
   PubMed Web of Science ®Google Scholar
• FileTMJrCurrent challenges in the treatment of community-acquired pneumoniaClin Infect Dis200438Suppl 1S1S4
   PubMedGoogle Scholar
• BreimanRFButlerJCTenoverFCElliottJAFacklamRREmergence of drug-resistant pneumococcal infections in the United StatesJAMA1994271183118358196139
   PubMed Web of Science ®Google Scholar
• KarlowskyJAThornsberryCJonesMEEvangelistaATCritchleyIASahmDFFactors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002)Clin Infect Dis20033696397012684907
   PubMed Web of Science ®Google Scholar
• ThornsberryCSahmDFKellyLJRegional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000Clin Infect Dis200234Suppl 1S4S1611810606
   PubMed Web of Science ®Google Scholar
• JenkinsSGBrownSDFarrellDJTrends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4Ann Clin Microbiol Antimicrob200871.b18190701
   PubMedGoogle Scholar
• SahmDFBrownNPThornsberryCJonesMEAntimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspectivePostgrad Med20081203 Suppl 1162418931467
   PubMed Web of Science ®Google Scholar
• HoaNQTrungNVLarssonMDecreased Streptococcus pneumoniae susceptibility to oral antibiotics among children in rural Vietnam: a community studyBMC Infect Dis2010108520356399
   PubMed Web of Science ®Google Scholar
• Kosowski-ShickKMcGheePAppelbaumPAffinity of ceftraoline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Strepotococcus pneumoniaeAntimicrob Agents Chemother2010541670167720194704
   PubMed Web of Science ®Google Scholar
• MushtaqSWarnerMGeYKanigaKLivermoreDIn vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypesJ Antimicrob Chemother20076030031117548456
   PubMed Web of Science ®Google Scholar
• IshikawaTMatsunagaNTawadaHTAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological propertiesBioorg Med Chem2003112427243712735989
   PubMed Web of Science ®Google Scholar
• MoisanHPruneauMMalouinFBinding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniaeJ Antimicrob Chemother20106571371620097788
   PubMed Web of Science ®Google Scholar
• Villegas-EstradaALeeMHesekDCo-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA b-lactam antibioticsJ Am Chem Soc20081309212921318582062
   PubMed Web of Science ®Google Scholar
• BiekDCritchleyIARiccobeneTAThyeDACeftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-gram-positive activityJ Antimicrob Chemother201065Suppl 4iv9iv1621115457
   PubMed Web of Science ®Google Scholar
• SaravolatzLDSteinGEJohnsonLBCeftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Reviews of anti-infective agentsClin Infect Dis2011521156116321467022
   PubMed Web of Science ®Google Scholar
• GeYBiekDTalbotGHSahmDFIn vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United StatesAntimicrob Agents Chemother20085293398340718625769
   PubMed Web of Science ®Google Scholar
• McGeeLBiekDGeYIn vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniaAntimicrob. Agents Chemother200953255219015339
   PubMed Web of Science ®Google Scholar
• DoernGVDiekemaDJHeilmannKPDohrnCLRiahiFRichterSSIn vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010–2011Antimicrob. Agents Chemother2012566340622491687
   PubMed Web of Science ®Google Scholar
• RiccobeneTFangEThyeDAA single-and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects [Abstract 1888]Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy–46th Annual Meeting of the Infectious Diseases Society of AmericaWashington, DCAmerican Society of Microbiology2008
   Google Scholar
• GeJYHubbelAIn vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M) [Abstract 1935]Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, CA2006
   Google Scholar
• MoutonJWDudleyMNCarsOStandardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJ Antimicrob Chemother20055560160715772142
   PubMed Web of Science ®Google Scholar
• MacGowanAPNoelARTomaselliSBowkerKEPharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infectionAntimicrob Agents Chemother2013576245123459495
   PubMed Web of Science ®Google Scholar
• TalbotGHThyeDDasAGeYPhase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsAntimicrob Agents Chemother20075110361217682094
   PubMed Web of Science ®Google Scholar
• CoreyGRWilcoxMHTalbotGHThyeDFriedlandDBaculikTCANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsJ Antimicrob Chemother201065Suppl 4iv41iv5121115454
   PubMed Web of Science ®Google Scholar
• WilcoxMHCoreyGRTalbotGHCANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsJ Antimicrob Chemother201065Suppl 4iv53iv6521115455
   PubMed Web of Science ®Google Scholar
• CoreyGRWilcoxMTalbotGHIntegrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infectionClin Infect Dis201051664165020695801
   PubMed Web of Science ®Google Scholar
• FriedlandHDO’NealTBiekDCANVAS 1 and 2: Analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infectionsAntimicrob Agents Chemother2012565223122314524
   PubMed Web of Science ®Google Scholar
• FileJMJrLowDEEckburgPBFOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaJ Antimicrob Chemother201166Suppl 3iii19iii3221482566
   PubMed Web of Science ®Google Scholar
• LowDEFileTMJrEckburgPBFOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaJ Antimicrob Chemother201166Suppl 3iii33iii4421482568
   PubMed Web of Science ®Google Scholar
• FileTMJrLowDEEckburgPBIntegrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumoniaClin Infect Dis201051121395140521067350
   PubMed Web of Science ®Google Scholar
• CasapaoAMDavisSLBarrVOLarge retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapyAntimicrob Agents Chemother2014585254124550331
   PubMed Web of Science ®Google Scholar
• medicines.org.ukZinforo Available from: http://www.medicines.org.uk/emc/medicine/26988/SPC/Zinforo+600+mg+powder+for+concentrate+for+solution+for+infusion/Accessed Januray 9 2015
   Google Scholar
• Teflaro [prescribing information]Teramo, ItalyForest Laboratories, Inc2010–2012
   Google Scholar
• British National Formulary66th EditionSeptember 2013 – March 2014 BMJ Group and Royal Pharmaceutical Society of Great Britain2013363
   Google Scholar